Ipca Labs Q2 Review - Weak Quarter; Outlook Remains Positive: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Ipca Laboratories Ltd.’s Q2 performance was weak and should recover from Q4 FY22/Q1 FY23. The company's sales at Rs 15.4 billion, grew 14% YoY.
Domestic business grew 30% YoY aided by low base while export formulation growth was muted with 4% YoY decline.
Institutional business declined 22% YoY, mainly impacted by delay in shipments. Branded generics grew by 4.5% YoY while generics grew 1% YoY.
Export API declined by 12% QoQ largely on reduced order flow. Domestic API grew strongly by 25% YoY. Revenue from subsidiaries was higher in Q2 at Rs 1.2 billion.
Ipca Labs reported weak Ebitda margins of 22.4%, down 400 bps QoQ due to increase in commodity prices and logistic costs. During the quarter, raw material prices increased 17% YoY versus revenue growth of 10%.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.